243 related articles for article (PubMed ID: 31030490)
1. Programmed Death Ligand 1 (PD-L1) Expression in Epithelial Ovarian Cancer: A Comparison of Type I and Type II Tumors.
Nhokaew W; Kleebkaow P; Chaisuriya N; Kietpeerakool C
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1161-1169. PubMed ID: 31030490
[TBL] [Abstract][Full Text] [Related]
2. [Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer].
Ju C; Gao JC; Zhang PX; Zhang KN; Yang S; Kang TJ; Zhao HZ; Qi WJ; Zhang QP; Kong FD; Guan HW; Shi H
Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):529-534. PubMed ID: 32854477
[No Abstract] [Full Text] [Related]
3. CD105/Ki67 coexpression correlates with tumor progression and poor prognosis in epithelial ovarian cancer.
Liu P; Sun YL; Du J; Hou XS; Meng H
Int J Gynecol Cancer; 2012 May; 22(4):586-92. PubMed ID: 22266931
[TBL] [Abstract][Full Text] [Related]
4. CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer.
Chen X; Zhang J; Cheng W; Chang DY; Huang J; Wang X; Jia L; Rosen DG; Zhang W; Yang D; Gershenson DM; Sood AK; Bast RC; Liu J
Int J Gynecol Cancer; 2013 Jun; 23(5):815-22. PubMed ID: 23669443
[TBL] [Abstract][Full Text] [Related]
5. Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer.
Brandt S; Samartzis EP; Zimmermann AK; Fink D; Moch H; Noske A; Dedes KJ
BMC Cancer; 2017 Jan; 17(1):44. PubMed ID: 28073364
[TBL] [Abstract][Full Text] [Related]
6. Elevated growth differentiation factor 15 expression predicts poor prognosis in epithelial ovarian cancer patients.
Zhang Y; Hua W; Niu LC; Li SM; Wang YM; Shang L; Zhang C; Li WN; Wang R; Chen BL; Xin XY; Zhang YQ; Wang J
Tumour Biol; 2016 Jul; 37(7):9423-31. PubMed ID: 26781874
[TBL] [Abstract][Full Text] [Related]
7. EphA8 is a prognostic marker for epithelial ovarian cancer.
Liu X; Xu Y; Jin Q; Wang W; Zhang S; Wang X; Zhang Y; Xu X; Huang J
Oncotarget; 2016 Apr; 7(15):20801-9. PubMed ID: 26989075
[TBL] [Abstract][Full Text] [Related]
8. Outcome in serous ovarian cancer is not associated with LATS expression.
Montavon C; Stricker GR; Schoetzau A; Heinzelmann-Schwarz V; Jacob F; Fedier A
J Cancer Res Clin Oncol; 2019 Nov; 145(11):2737-2749. PubMed ID: 31586262
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of Dynamin related protein 1 (Drp1) in epithelial ovarian cancer.
Tsuyoshi H; Orisaka M; Fujita Y; Asare-Werehene M; Tsang BK; Yoshida Y
BMC Cancer; 2020 May; 20(1):467. PubMed ID: 32448194
[TBL] [Abstract][Full Text] [Related]
10. Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma.
Sung PL; Jan YH; Lin SC; Huang CC; Lin H; Wen KC; Chao KC; Lai CR; Wang PH; Chuang CM; Wu HH; Twu NF; Yen MS; Hsiao M; Huang CY
Oncotarget; 2016 Jan; 7(4):4036-47. PubMed ID: 26716408
[TBL] [Abstract][Full Text] [Related]
11. IL17a and IL21 combined with surgical status predict the outcome of ovarian cancer patients.
Chen YL; Chou CY; Chang MC; Lin HW; Huang CT; Hsieh SF; Chen CA; Cheng WF
Endocr Relat Cancer; 2015 Oct; 22(5):703-11. PubMed ID: 26150382
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma.
Zhu J; Wen H; Bi R; Wu Y; Wu X
J Gynecol Oncol; 2017 Nov; 28(6):e77. PubMed ID: 29027395
[TBL] [Abstract][Full Text] [Related]
13. Mucinous, endometrioid, and serous ovarian cancers with peritoneal dissemination are potent candidates for P-cadherin targeted therapy: a retrospective cohort study.
Kayahashi K; Mizumoto Y; Matsuoka A; Obata T; Iwadare J; Nakamura M; Daikoku T; Fujiwara H
BMC Cancer; 2021 Jan; 21(1):32. PubMed ID: 33413178
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of Annexin A1 Is an Independent Predictor of Longer Overall Survival in Epithelial Ovarian Cancer.
Manai M; Doghri R; Finetti P; Mrad K; Bouabsa R; Manai M; Birnbaum D; Bertucci F; Charfi L; Driss M
In Vivo; 2020; 34(1):177-184. PubMed ID: 31882477
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the clinicopathological relevance of mesothelin level in plasma, peritoneal fluid, and tumor tissue of epithelial ovarian cancer patients.
Okła K; Surówka J; Frąszczak K; Czerwonka A; Kaławaj K; Wawruszak A; Kotarski J; Wertel I
Tumour Biol; 2018 Oct; 40(10):1010428318804937. PubMed ID: 30319054
[TBL] [Abstract][Full Text] [Related]
16. Up-regulation of cadherin 17 and down-regulation of homeodomain protein CDX2 correlate with tumor progression and unfavorable prognosis in epithelial ovarian cancer.
Huang LP; Yu YH; Sheng C; Wang SH
Int J Gynecol Cancer; 2012 Sep; 22(7):1170-6. PubMed ID: 22810971
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
[TBL] [Abstract][Full Text] [Related]
18. Dualistic classification of epithelial ovarian cancer: surgical and survival outcomes in a large retrospective series.
Panici PB; Marchetti C; Salerno L; Musella A; Vertechy L; Palaia I; Perniola G; Ruscito I; Boni T; Angioli R; Muzii L
Ann Surg Oncol; 2014 Sep; 21(9):3036-41. PubMed ID: 24770721
[TBL] [Abstract][Full Text] [Related]
19. Adenosine triphosphate-based chemotherapy response assay predicts long-term survival of primary epithelial ovarian cancer.
Li LY; Kim SW; Nam EJ; Lee J; Kim S; Kim YT
Int J Gynecol Cancer; 2019 Feb; 29(2):334-340. PubMed ID: 30718314
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC).
Mesnage SJL; Auguste A; Genestie C; Dunant A; Pain E; Drusch F; Gouy S; Morice P; Bentivegna E; Lhomme C; Pautier P; Michels J; Le Formal A; Cheaib B; Adam J; Leary AF
Ann Oncol; 2017 Mar; 28(3):651-657. PubMed ID: 27864219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
